METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING CANDIDA AURIS IN BLOOD
A method for treating Candida Auris in blood, comprising administering to the blood taurolidine, and/or one or more taurolidine derivatives, in a concentration which is effective to treat C. Auris in the blood.
1 . A method for treating Candida Auris in blood, comprising administering to the blood taurolidine, and/or one or more taurolidine derivatives, in a concentration which is effective to treat C. Auris in the blood.
2 . A method according to claim 1 wherein the taurolidine, and/or the one or more taurolidine derivatives, is in a nanoparticle delivery system.
3 . A method according to claim 2 wherein the nanoparticle delivery system comprises a nanoparticle comprising a solid core of taurolidine, and/or the one or more taurolidine derivatives, covered by a solid excipient coating.
4 . A method according to claim 3 wherein the taurolidine, and/or the one or more taurolidine derivatives, comprise(s) a powder, and further wherein the solid excipient coating comprises a solid polymer.
5 . A method according to claim 4 wherein the solid polymer comprises one from the group consisting of polylactide and polylactate.
6 . A method according to claim 4 wherein the solid polymer comprises a polysaccharide that specifically binds to fungal mannoproteins.
7 . A method according to claim 6 wherein the polysaccharide comprises chitosan, starch or alginate.
8 . A method according to claim 3 wherein the nanoparticle delivery system further comprises a carrier.
9 . A method according to claim 8 wherein the carrier comprises a hyaluronic acid hydrogel.
10 . A method according to claim 2 wherein the nanoparticle delivery system comprises a nanoparticle comprising a liquid core of taurolidine, and/or the one or more taurolidine derivatives, covered by a solid excipient coating.
11 . A method according to claim 10 wherein the liquid core comprises a solution or a suspension, and further wherein the solid excipient coating comprises a solid polymer.
12 . A method according to claim 11 wherein the solid polymer comprises one from the group consisting of polylactide and polylactate.
13 . A method according to claim 11 wherein the solid polymer comprises a polysaccharide that specifically binds to fungal mannoproteins.
14 . A method according to claim 13 wherein the polysaccharide comprises chitosan, starch or alginate.
15 . A method according to claim 10 wherein the nanoparticle delivery system further comprises a carrier.
16 . A method according to claim 15 wherein the carrier comprises a hyaluronic acid hydrogel.
17 . A method according to claim 2 wherein the nanoparticle delivery system comprises a nanoparticle comprising a liquid core of taurolidine, and/or the one or more taurolidine derivatives, carried by a porous body which is then sealed with a solid excipient coating.
18 . A method according to claim 17 wherein the liquid core comprises a solution or a suspension, the porous body comprises a porous sphere or nanotube, and the solid excipient coating comprises a solid polymer.
19 . A method according to claim 18 wherein the solid polymer comprises one from the group consisting of polylactide and polylactate.
20 . A method according to claim 18 wherein the solid polymer comprises a polysaccharide that specifically binds to fungal mannoproteins.
21 . A method according to claim 20 wherein the polysaccharide comprises chitosan, starch or alginate.
22 . A method according to claim 17 wherein the nanoparticle delivery system further comprises a carrier.
23 . A method according to claim 22 wherein the carrier comprises a hyaluronic acid hydrogel.
24 . A method according to claim 1 wherein the taurolidine, and/or the one or more taurolidine derivatives, is bound to a polymer for delivery to the therapy site.
25 . A method according to claim 24 wherein the polymer comprises polyethylene glycol (PEG).
26 . A method according to claim 1 wherein the taurolidine, and/or the one or more taurolidine derivatives, is dispersed in a polymer-carbohydrate-lipid conjugate or polymer-carbohydrate-lipid conjugates.
27 . A method according to claim 26 wherein the polymer-carbohydrate-lipid conjugate or the polymer-carbohydrate-lipid conjugates comprise a PEG-carbohydrate-lipid conjugate.
28 . A method according to claim 27 wherein the PEG-carbohydrate-lipid conjugate comprises oieoyltri-ethylenetetramine-polyethyleneglycol lactobionate.
29 . A method according to claim 27 wherein the PEG-carbohydrate-lipid conjugate comprises oleoyldiethylenetetramine-dodecaethylene glycol lactobionate.
30 .- 54 . (canceled)